Anna French holds a D.Phil. from Oxford in stem cell science and moved through Boston Consulting Group's healthcare strategy group before becoming the first employee to help build Qiming Venture Partners USA, giving her a science-first, builder's path into venture investing focused on cell and regenerative medicine. She's known for backing technically ambitious bets like Umoja Biopharma's in vivo CAR-T and in-house manufacturing approach, sits closely involved on boards such as Umoja, Empirico, and Jasper Therapeutics, and has recently extended her interest beyond therapeutics into infrastructure companies like Rhino Federated Computing and Altis Labs.